Cargando…

Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy

Here, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bošnjak, Berislav, Odak, Ivan, Ritter, Christiane, Stahl, Klaus, Graalmann, Theresa, Steinbrück, Lars, Blasczyk, Rainer, Falk, Christine S., Schulz, Thomas F., Wedemeyer, Hans Heinrich, Cornberg, Markus, Ganser, Arnold, Förster, Reinhold, Koenecke, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387963/ https://www.ncbi.nlm.nih.gov/pubmed/34456929 http://dx.doi.org/10.3389/fimmu.2021.721738

Ejemplares similares

NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity
por: Barros-Martins, Joana, et al.
Publicado: (2022)

Hide and seek with SARS-CoV-2: spike receptor-binding domain-specific memory B cells still recognize Omicron variant
por: Odak, Ivan, et al.
Publicado: (2022)

Reappearance of effector T cells is associated with recovery from COVID-19
por: Odak, Ivan, et al.
Publicado: (2020)

Distribution of major lymphocyte subsets and memory T-cell subpopulations in healthy adults employing GLP-conforming multicolor flow cytometry
por: Schultze-Florey, Christian R., et al.
Publicado: (2021)

Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern
por: Odak, Ivan, et al.
Publicado: (2022)

Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy
por: Ravens, Sarina, et al.
Publicado: (2018)

Challenges of CRISPR-Based Gene Editing in Primary T Cells
por: Rezalotfi, Alaleh, et al.
Publicado: (2022)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

CAR NK Cell Therapy for T Follicular Helper Cells
por: King, Cecile
Publicado: (2020)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
por: Ramezani, Faezeh, et al.
Publicado: (2023)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

CAR‐NK cells: the next wave of cellular therapy for cancer
por: Daher, May, et al.
Publicado: (2021)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

Neurological management and work-up of neurotoxicity associated with CAR T cell therapy
por: Möhn, Nora, et al.
Publicado: (2022)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Abstract 2 Development of CAR-NK Cell Therapy for Hematologic Malignancies
por: Stoltzman, Carrie, et al.
Publicado: (2022)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours
por: White, Lydia G., et al.
Publicado: (2022)

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
por: Ruppel, Katharina Eva, et al.
Publicado: (2022)

Efficient IL-2R signaling differentially affects the stability, function, and composition of the regulatory T-cell pool
por: Permanyer, Marc, et al.
Publicado: (2021)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
por: Gurney, Mark, et al.
Publicado: (2021)

Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology
por: Schmidt, Paula, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
por: Liu, Tingdang, et al.
Publicado: (2023)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype
por: Bhardwaj, Suvercha, et al.
Publicado: (2016)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Hematopoietic stem cell‐ and induced pluripotent stem cell‐derived CAR‐NK cells as reliable cell‐based therapy solutions
por: Arias, Jonathan, et al.
Publicado: (2021)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Donor-derived IL-17A and IL-17F deficiency triggers Th1 allo-responses and increases gut leakage during acute GVHD
por: Odak, Ivan, et al.
Publicado: (2020)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1h9ii8972vr2vol8fev6la2lh0